Target intelligence / Profile preview

Clostridioides difficile surface layer protein A (SlpA) (SlpA)

Target
SlpA
Molecular classification
Bacterial surface protein, S-layer protein, Adhesin, Phage receptor, Enzyme (Cwp84)
01

Overview

Clostridioides difficile (formerly Clostridium difficile) bacterial cell surface receptors, primarily represented by the Surface Layer Protein A (SlpA) and a family of associated Cell Wall Proteins (CWPs), are critical structural and functional components of the bacterial envelope. SlpA is the most abundant protein on the vegetative cell surface, where it assembles into a paracrystalline S-layer that provides structural integrity and serves as a major adhesin for binding to the host's intestinal epithelium. These surface proteins are essential for the initial stages of colonization, biofilm formation, and the regulation of toxin secretion (TcdA and TcdB), which are the primary drivers of C. difficile infection (CDI) pathogenesis. Additionally, SlpA acts as a primary receptor for many C. difficile-specific bacteriophages and R-type bacteriocins, making it a high-priority target for narrow-spectrum therapeutic interventions. Targeting these receptors with monoclonal antibodies, vaccines, or phage-based therapies aims to prevent bacterial adhesion and colonization, thereby reducing the incidence and recurrence of CDI while preserving the protective gut microbiota.

Other names
Surface layer protein AS-layer proteinCell wall protein (CWP)SlpA precursorHigh-molecular-weight surface layer protein (HMW-SLP)Low-molecular-weight surface layer protein (LMW-SLP)Cwp84Cwp66Bacterial adhesinBile salt receptor CspC
02

Mechanism of action

Inhibition of bacterial adhesion to host cells, disruption of S-layer assembly, and phage-mediated bacterial lysis to prevent colonization and virulence.

03

Biological functions

AdhesionColonizationCell wall integrityBiofilm formationToxin secretionPhage bindingEnvironmental sensing
04

Disease associations

Clostridioides difficile infection (CDI)Antibiotic-associated diarrheaPseudomembranous colitisInfection
05

Safety considerations

High sequence variability of SlpA among different bacterial strainsPotential for immune evasion through phase variationChallenges in achieving broad-spectrum protection across all ribotypes
06

Interacting drugs

Avidocin-CD

3 more in the full profile.

07

Biomarkers

Anti-SlpA IgG antibodiesAnti-SlpA IgA antibodiesSlpA protein levels in stool

Beyond the preview

Go deeper on Clostridioides difficile surface layer protein A (SlpA) (SlpA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Clostridioides difficile surface layer protein A (SlpA) (SlpA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call